CA3113962C - Primary nk car constructs and methods - Google Patents
Primary nk car constructs and methods Download PDFInfo
- Publication number
- CA3113962C CA3113962C CA3113962A CA3113962A CA3113962C CA 3113962 C CA3113962 C CA 3113962C CA 3113962 A CA3113962 A CA 3113962A CA 3113962 A CA3113962 A CA 3113962A CA 3113962 C CA3113962 C CA 3113962C
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- sequence portion
- cells
- recombinant nucleic
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 23
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 64
- 210000004027 cell Anatomy 0.000 claims abstract description 57
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 53
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 46
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 46
- 230000003834 intracellular effect Effects 0.000 claims abstract description 26
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 18
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 12
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 21
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 21
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 20
- 230000001472 cytotoxic effect Effects 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 10
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 8
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 230000033001 locomotion Effects 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 58
- 108091026898 Leader sequence (mRNA) Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 46
- 201000010099 disease Diseases 0.000 description 31
- 201000011510 cancer Diseases 0.000 description 28
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 27
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 25
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 25
- 238000011282 treatment Methods 0.000 description 22
- 239000000427 antigen Substances 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 19
- 108020005345 3' Untranslated Regions Proteins 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 15
- 238000013519 translation Methods 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 14
- 230000000977 initiatory effect Effects 0.000 description 13
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 11
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000001086 cytosolic effect Effects 0.000 description 8
- 238000004520 electroporation Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 229940022399 cancer vaccine Drugs 0.000 description 6
- 238000009566 cancer vaccine Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000011581 secondary neoplasm Diseases 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 229950010131 puromycin Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical class NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- -1 antifungals Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 208000037819 metastatic cancer Diseases 0.000 description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 206010050017 Lung cancer metastatic Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 190000008236 carboplatin Chemical compound 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical group C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102100021186 Granulysin Human genes 0.000 description 1
- 101710168479 Granulysin Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 101000589301 Homo sapiens Natural cytotoxicity triggering receptor 1 Proteins 0.000 description 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 101800001494 Protease 2A Proteins 0.000 description 1
- 101800001066 Protein 2A Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- OPGTXAUDXWCGFI-UHFFFAOYSA-N [1-[[6-[[3-(3-dodecanoyloxytetradecanoylamino)-6-(hydroxymethyl)-5-phosphonooxy-4-(3-tetradecanoyloxytetradecanoyloxy)oxan-2-yl]oxymethyl]-2,4,5-trihydroxyoxan-3-yl]amino]-1-oxotetradecan-3-yl] hexadecanoate Chemical compound OC1C(O)C(NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(O)OC1COC1C(NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)C(OC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(OP(O)(O)=O)C(CO)O1 OPGTXAUDXWCGFI-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 101150087698 alpha gene Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003555 analeptic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940055075 anticholinesterase parasympathomimetics Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 101150058049 car gene Proteins 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 239000002372 hematologic agent Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000012966 malignant exocrine pancreas neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 229960001494 octreotide acetate Drugs 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 239000002243 precursor Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/46444—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Developmental Biology & Embryology (AREA)
Abstract
ABSTRACT
Disclosed herein are recombinant nucleic acids, comprising a 5' untranslated (5' -UTR) sequence portion, a signal peptide sequence portion, a single chain antibody fragment sequence portion, a hinge region sequence portion, a transmembrane domain sequence portion, and one or more intracellular domain sequence portions. Also disclosed herein are modified natural killer (NK) cells comprising the recombinant nucleic acid described above. Further disclosed herein are methods of treating a tumor in a subject by administering the modified NK cells.
Date Recue/Date Received 2021-03-31
Disclosed herein are recombinant nucleic acids, comprising a 5' untranslated (5' -UTR) sequence portion, a signal peptide sequence portion, a single chain antibody fragment sequence portion, a hinge region sequence portion, a transmembrane domain sequence portion, and one or more intracellular domain sequence portions. Also disclosed herein are modified natural killer (NK) cells comprising the recombinant nucleic acid described above. Further disclosed herein are methods of treating a tumor in a subject by administering the modified NK cells.
Date Recue/Date Received 2021-03-31
Description
PRIMARY NK CAR CONSTRUCTS AND METHODS
[0001]
Field of the Invention
[0001]
Field of the Invention
[0002] The field of the invention is recombinant nucleic acids and cells containing the same, particularly as they relate to the treatment of cancer.
Background of the Invention
Background of the Invention
[0003] The background description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
[0004] Cancer immunotherapies based on natural killer (NK) cells have had remarkable progress in recent years. NK cells are cytotoxic lymphocytes that constitute a significant component of the innate immune system. In most cases, NK cells represent about 4-10% of circulating lymphocytes, and bind and kill targeted cells, including virus-infected cells and many malignant cells. NK cell killing is non-specific with regard to particular antigens and can occur without prior immune sensitization. Killing of targeted cells is typically mediated by cytolytic proteins, including perforin, granzyme, and granuly sin.
[0005] NK cells have been used as therapeutic entities. To that end, NK cells are isolated from the peripheral blood lymphocyte fraction of whole blood, expanded in cell culture to obtain sufficient numbers of cells, and then re-infused into a subject. NK cells have shown in at least some cases moderate effectiveness in both ex vivo therapy and in vivo treatment. However, cancers employ various tactics to delay, alter, or even stop anti-tumor immunity, leading to failures in the control of tumor growth.
Date Recue/Date Received 2022-07-28
Date Recue/Date Received 2022-07-28
[0006] The anti-tumor response of NK cells also faces a lot of limitations.
First, the poor ability of NK cells to reach tumor tissues limits their application as therapies for solid tumors.
This is a common problem of cellular immunotherapy strategies. Second, changes in NK cell-activating receptors and their ligands in tumors, may lead to a decreased therapeutic response and tumor progression. For example, high levels of NKG2D (Natural-killer Group 2, Member D) ligands are detected in the early stages of colorectal cancer, but their expression decreases as the disease progresses. Third, the tumor microenvironment (TME) remains a major barrier to the effectiveness of adoptively transferred NK cells. For example, tumor-infiltrating immune cells such as dendritic cells (DCs), suppressive or tolerogenic macrophages and regulatory T (Treg) cells as well as cancer-associated fibroblasts, which are embedded in the extracellular matrix, may meddle in NK cell activation either through secretion of immunosuppressive cytokines or by interfering with receptor expression.
First, the poor ability of NK cells to reach tumor tissues limits their application as therapies for solid tumors.
This is a common problem of cellular immunotherapy strategies. Second, changes in NK cell-activating receptors and their ligands in tumors, may lead to a decreased therapeutic response and tumor progression. For example, high levels of NKG2D (Natural-killer Group 2, Member D) ligands are detected in the early stages of colorectal cancer, but their expression decreases as the disease progresses. Third, the tumor microenvironment (TME) remains a major barrier to the effectiveness of adoptively transferred NK cells. For example, tumor-infiltrating immune cells such as dendritic cells (DCs), suppressive or tolerogenic macrophages and regulatory T (Treg) cells as well as cancer-associated fibroblasts, which are embedded in the extracellular matrix, may meddle in NK cell activation either through secretion of immunosuppressive cytokines or by interfering with receptor expression.
[0007] Thus there remains a need in the art for technologies and methods for overcome the above problems and being able modify NK cells for specific targeting of cancer cells.
Summary of The Invention
Summary of The Invention
[0008] The inventive subject matter is directed to recombinant nucleic acids, comprising a T7 promoter sequence portion, a 5' untranslated (5'-UTR) sequence portion, a signal peptide sequence portion, a single chain antibody fragment sequence portion, a hinge region sequence portion, a transmembrane domain sequence portion, and one or more intracellular domain sequence portions.. The recombinant nucleic acid may further comprises a sequence encoding CD64. Furthermore, the 5'-UTR sequence portion may further comprise a kozak sequence.
[0009] Preferably, the single chain antibody fragment sequence portion comprises a sequence encoding for a single chain variable fragment that is adapted to bind PDL1 antigen or other tumor antigens. In some embodiment, the recombinant nucleic acid may further comprise a sequence portion encoding CD16a and/or ER-IL2.
[0010] The hinge sequence portion provides range of motion for the single chain antibody fragment sequence portion, while the transmembrane domain sequence portion enables insertion of the recombinant nucleic acid to a membrane.
[0011] The intracellular domain sequence portion of the recombinant nucleic acid as disclosed herein is contemplated to comprise co-stimulatory or signaling sequence portions.
Date Recue/Date Received 2021-03-31 In one embodiment, the intracellular domain sequence portion comprises CD28 and/or CD3c.
In another embodiment, the intracellular domain sequence portion comprises CD28 and/or FceRIy. The recombinant nucleic acid of any one of the preceding claims, Furthermore, the intracellular domain sequence portion may provide enhanced cytotoxic activity against tumor cells.
Date Recue/Date Received 2021-03-31 In one embodiment, the intracellular domain sequence portion comprises CD28 and/or CD3c.
In another embodiment, the intracellular domain sequence portion comprises CD28 and/or FceRIy. The recombinant nucleic acid of any one of the preceding claims, Furthermore, the intracellular domain sequence portion may provide enhanced cytotoxic activity against tumor cells.
[0012] Preferably, the recombinant nucleic acid of this disclosure comprises a 3'-untranslated region (3'-UTR) and a poly-A sequence portion. The 3'-UTR sequence portion provides RNA stability and initiation of translation. The poly-A sequence portion preferably comprises at least 150 adenine nucleotides. The poly-A sequence portion provides RNA
stability and initiation of translation.
stability and initiation of translation.
[0013] The recombinant nucleic acid vector of this disclosure is preferably optimized to target a tumor antigen. In some embodiments, the recombinant nucleic acid has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 1. In other embodiments, the recombinant nucleic acid has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 2. In still other embodiments, the recombinant nucleic acid, has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 3. In still further embodiments, the recombinant nucleic acid, has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID
NO: 4.
NO: 4.
[0014] In another aspect of the inventive subject matter, the inventors have disclosed a modified NK cell comprising one or more nucleic acids encoding: a 5' untranslated (5'-UTR) sequence portion, a signal peptide sequence portion, a single chain antibody fragment sequence portion, a hinge region sequence portion, a transmembrane domain sequence portion, and one or more intracellular domain sequence portions; wherein the nucleic acid sequences are operably linked to each other as a single polynucleotide. This modified NK cell is contemplated to specifically target tumor cells.
[0015] In another aspect, the inventors have disclosed a method of generating modified NK
cells or CAR-NK cells, comprising: transfecting a primary NK cell with a recombinant nucleic acid as disclosed above. Furthermore, a composition is also disclosed comprising the modified NK cell and a pharmaceutically acceptable excipient. Furthermore, the modified Date Recue/Date Received 2021-03-31 NK cell may be provided in a kit; for example the kit may comprise the NK cell as disclosed herein and instructions for use.
cells or CAR-NK cells, comprising: transfecting a primary NK cell with a recombinant nucleic acid as disclosed above. Furthermore, a composition is also disclosed comprising the modified NK cell and a pharmaceutically acceptable excipient. Furthermore, the modified Date Recue/Date Received 2021-03-31 NK cell may be provided in a kit; for example the kit may comprise the NK cell as disclosed herein and instructions for use.
[0016] In yet another aspect, disclosed is a method of treating a cancer or a tumor in a subject, the method comprising administering to the subject a therapeutically effective amount of the modified NK cells or the composition comprising the modified NK cells, wherein administration treats the cancer or reduces the size of the tumor in the subject. A method of reducing cancer metastasis in a patient is also contemplated, wherein a subject having cancer metastasis is administered with a therapeutically effective amount of the modified NK cells or a composition comprising modified NK cells. Preferably, from lx 103 to 1 x 1010, per 2 m of the NK cells are administered to the subject. The administration may be done parenterally, intravenously, peritumorally, or by infusion. The method may also comprise further administration to the subject an additional therapeutic agent.
[0016a] In another aspect, disclosed is a recombinant cell comprising the recombinant nucleic acid as disclosed above, wherein the cell is a bacterial cell or wherein the cell is an autologous NK cell, or wherein the NK cell is genetically modified.
[0016a] In another aspect, disclosed is a recombinant cell comprising the recombinant nucleic acid as disclosed above, wherein the cell is a bacterial cell or wherein the cell is an autologous NK cell, or wherein the NK cell is genetically modified.
[0017] In another embodiment, the inventors have disclosed a method of treating cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of any one of the genetically modified NK cells as disclosed herein, thereby treating the cancer. The method may further comprise a step of administering at least one additional therapeutic entity selected from the group consisting of a viral cancer vaccine, a bacterial cancer vaccine, a yeast cancer vaccine, N-803, an antibody, a stem cell transplant, and a tumor targeted cytokine. The cancer is selected from leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, chronic leukemias, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, polycythemia vera, lymphomas, Hodgkin's disease, non-Hodgkin's disease, multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyo sarcoma, colon carcinoma, pancreatic cancer, breast cancer, Date Recue/Date Received 2022-07-28 ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, 4a Date Recue/Date Received 2022-07-28 glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma and retinoblastoma.
[0018] Various objects, features, aspects and advantages of the inventive subject matter will become more apparent from the following detailed description of preferred embodiments, along with the accompanying drawing figures in which like numerals represent like components.
Brief Description of The Drawing
Brief Description of The Drawing
[0019] Fig.1 depicts one embodiment of generation of a chimeric antigen targeted at PDL1 protein: pNBS-XL53.
[0020] Fig.2 shows one embodiment of the time course of XL53 PDL1 CAR
expression post electroporation.
expression post electroporation.
[0021] Fig.3 illustrates one embodiment of the cytotoxic activity on fLuc expressing U251 and MS1 target cells.
[0022] Fig.4 shows one embodiment of a vector map of the XL53 construct.
[0023] Fig.5 shows one embodiment of generation of a chimeric antigen targeted at PDL1 protein, pNBS-XL53-150A.
[0024] Fig.6 illustrates one embodiment of a time course of XL53-150A PDL1 CAR
expression post electroporation.
expression post electroporation.
[0025] Fig.7 illustrates one embodiment of cytotoxic activity of NK cells transfected with XL53-150A.
[0026] Fig.8 shows one embodiment of a vector map of the XL53-150A construct.
[0027] Fig.9 shows one embodiment of generation of a chimeric antigen targeted at PDL1 protein, NKW29-150A.
[0028] Fig.10 depicts one embodiment of time course of NKW29-150A PDL1 CAR
expression in NK cells.
Date Recue/Date Received 2021-03-31
expression in NK cells.
Date Recue/Date Received 2021-03-31
[0029] Fig.11 illustrates one embodiment of a vector map of the NKW29-150A
construct.
construct.
[0030] Fig.12 illustrates one embodiment of generation of a chimeric antigen targeted at PDLI
protein, vicistronic XL35.
protein, vicistronic XL35.
[0031] Fig.13 illustrates one embodiment of XL53-tricistronic PDL1 CAR
expression 24 hours post electroporation.
expression 24 hours post electroporation.
[0032] Fig.14 depicts one embodiment of cytotoxic activity of CAR-infected cells on MS1 fLuc target cells.
[0033] Fig.15 illustrates one embodiment of vector map of the XL53-tricistronic construct.
Detailed Description
Detailed Description
[0034] Where a definition or use of a term in a reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0035] The inventors have disclosed herein various engineered NK cells as the basis to improve immunotherapies to cancer and tumors. Viewed from a different perspective, the inventors have disclosed nucleic acid constructs that target tumor antigens. Preferably, in some embodiments, the tumor antigen is PDLl. In one embodiment, these nucleic acid constructs may be chimeric antigen receptor constructs for transfecting primary NK cells to generate CAR-NK cells.
[0036] In one aspect of the inventive concept, the disclosure herein involves generation of a chimeric antigen RNA molecule (CAR) against PDLI and potentially other tumor antigen targets. The RNA generated from these type of DNA constructs is contemplated to be delivered to natural killer cells for specific targeting of tumor cells.
Date Recue/Date Received 2022-07-28
Date Recue/Date Received 2022-07-28
[0037] In one embodiment, disclosed herein is a recombinant nucleic acid, comprising: a T7 promoter sequence portion, a 5' untranslated (5'-UTR) sequence portion, a signal peptide sequence portion, a single chain antibody fragment sequence portion, a hinge region sequence portion, a transmembrane domain sequence portion, and one or more intracellular domain sequence portions. In one embodiment, the recombinant nucleic acid comprises or consists of or consists essentially of an amino acid sequence having at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence homology to the nucleotide sequence of SEQ ID
NOs:1-4.
NOs:1-4.
[0038] The recombinant nucleic acid construct of SEQ ID NO: 1, also referred to herein as XL53, is targeted against a PD1 ligand called PDL1. This molecule is designed for in vitro synthesis of an RNA molecule that would be delivered to natural killer cells for the purpose of immunotherapy in cancer patients. In vitro transcription can be initiated at the T7 promoter using the bacteriophage T7 RNA polymerase. The T7 promoter is flanked by a 42-bp untranslated sequence (5' UTR: 5' untranslated) that also contains a Kozak sequence upstream of the CAR gene. The secondary structure of the 5' UTR along with the Kozak sequence aid with the initiation of translation. A short signal peptide (15-amino acids) from the CD64 protein, marks the N-terminus of the CAR protein. The signal peptide is recognized by a signal recognition peptide (SRP) in the cytosol that delivers the nascent polypeptide chain from the cytosol to the endoplasmic reticulum. The PDL1 binding site is a heterodimer of variable light and heavy chain domains. The two domains are connected to each other via a 20-aa (amino acids) linker. This hinge and transmembrane domains of the molecule are derived from the CD28 protein. The hinge region provides range of motion and flexibility for the binding domain while the transmembrane region allows correct membrane insertion. The cytoplasmic domains of CD28 and CD3c are co-stimulatory domains engaged in intracellular signaling pathways that enhance cytotoxic activities of the transfected cells.
At the 3' untranslated end of the construct, a 94-bp sequence from 3' UTR of Mus musculus hemoglobin alpha gene, further stabilizes the construct. This 3'UTR is followed by 22-bp polyA stretch. The combination of the 3' UTR and poly A confer stability to the RNA
molecule. The main features of the construct of SEQ ID NO: 1 are that (a) it has a high binding affinity for the PDL1 protein; (b) it uses a combination of intracellular domains of CD28 and CD3c for enhanced cytotoxic activity against target cells; and (c) it is RNA based, so there is no concern regarding integration of the construct into the host genome.
Date Recue/Date Received 2021-03-31
At the 3' untranslated end of the construct, a 94-bp sequence from 3' UTR of Mus musculus hemoglobin alpha gene, further stabilizes the construct. This 3'UTR is followed by 22-bp polyA stretch. The combination of the 3' UTR and poly A confer stability to the RNA
molecule. The main features of the construct of SEQ ID NO: 1 are that (a) it has a high binding affinity for the PDL1 protein; (b) it uses a combination of intracellular domains of CD28 and CD3c for enhanced cytotoxic activity against target cells; and (c) it is RNA based, so there is no concern regarding integration of the construct into the host genome.
Date Recue/Date Received 2021-03-31
[0039] Fig. 1 illustrates generation of a chimeric antigen targeted at PDL1 protein. The transcription of RNA is initiated by the T7 promoter. The 5'-UTR/Kozak region of nucleotides provides significant for initiation of translation. The nucleic acid sequence encoding he CD64 signal peptide is present in the 3' end of the UTR/Kozak region, and it directs nascent protein to ER. This is followed by scFv region, which binds PDL1 antigen.
A hinge region is present next to the scFv region, and that provides a range of motion to the scFv. The hinge region is followed by a transmembrane domain that allows insertion of the nucleotide construct into the membrane. This is followed by one or more intracellular domains comprising co-stimulatory and/or signaling elements. Finally, the 3'-UTR and Poly-A regions are present to provide stability to the RNA as well as initiation of translation.
A hinge region is present next to the scFv region, and that provides a range of motion to the scFv. The hinge region is followed by a transmembrane domain that allows insertion of the nucleotide construct into the membrane. This is followed by one or more intracellular domains comprising co-stimulatory and/or signaling elements. Finally, the 3'-UTR and Poly-A regions are present to provide stability to the RNA as well as initiation of translation.
[0040] Fig. 2 illustrates time course of XL53 PDL1 CAR expression post electroporation, while the cytotoxic activity on fLuc expressing U251 and MS1 target cells are shown in Fig.
3. The cytotoxic assay, as illustrated in Fig. 3, was set up to 2 hours post transfection and after overnight incubation. The vector map of the XL53 construct is shown in Fig. 4. Finally, Table 1 below shows the different sequence portions of the XL53 construct.
Table 1 pNBS-XL-53(Rbsc6-CD28CD3z-anti-PDL1) Size 7584 bp 3'UTR Mus Musculus 1-94 hemoglobin alpha polyA 95-116 SV40 polyA signal 433-567 Puromycin resistance gene 572-1171 (reverse) OriP 3187-3753 Ampicillin resistance gene 3842-4702 rrnG terminator 4700-4835 EFla promoter 4879-6060 T7 promoter 6068-6086 5'UTR 6087-6192 Kozak sequence 6123-6130 CD64 signal peptide 6132-6176 Rbsc6-VL (variable light 6177-6500 chain) Linker 6501-6560 Rbsc6-VH (variable heavy 6561-6914 chain) CD28 hinge region 6915-7031 CD28 transmembrane domain 7032-7112 Date Recue/Date Received 2021-03-31 CD28 cytoplasmic domain 7113-7235 CD3 cytoplasmic domain 7236-7577
3. The cytotoxic assay, as illustrated in Fig. 3, was set up to 2 hours post transfection and after overnight incubation. The vector map of the XL53 construct is shown in Fig. 4. Finally, Table 1 below shows the different sequence portions of the XL53 construct.
Table 1 pNBS-XL-53(Rbsc6-CD28CD3z-anti-PDL1) Size 7584 bp 3'UTR Mus Musculus 1-94 hemoglobin alpha polyA 95-116 SV40 polyA signal 433-567 Puromycin resistance gene 572-1171 (reverse) OriP 3187-3753 Ampicillin resistance gene 3842-4702 rrnG terminator 4700-4835 EFla promoter 4879-6060 T7 promoter 6068-6086 5'UTR 6087-6192 Kozak sequence 6123-6130 CD64 signal peptide 6132-6176 Rbsc6-VL (variable light 6177-6500 chain) Linker 6501-6560 Rbsc6-VH (variable heavy 6561-6914 chain) CD28 hinge region 6915-7031 CD28 transmembrane domain 7032-7112 Date Recue/Date Received 2021-03-31 CD28 cytoplasmic domain 7113-7235 CD3 cytoplasmic domain 7236-7577
[0041] In another embodiment, the inventors have disclosed the molecule XL53-150A, which comprises the recombinant nucleic acid construct of SEQ ID NO: 2. This molecule is similar to the XL53 molecule except for the following modifications: A 150-polyA
stretch is added to the 3' untranslated end of the construct to further stabilize the RNA
molecule. Also an internal Sapl restriction site is removed from the construct, while the same site is added at the end of the poly A tail. After linearization of the DNA template with Sapl, only A nucleotides remain. This further enhances translation of the RNA molecule. The main features of this construct are that it has a longer poly A tail, and it has a more prolonged half-life compared to XL53.
stretch is added to the 3' untranslated end of the construct to further stabilize the RNA
molecule. Also an internal Sapl restriction site is removed from the construct, while the same site is added at the end of the poly A tail. After linearization of the DNA template with Sapl, only A nucleotides remain. This further enhances translation of the RNA molecule. The main features of this construct are that it has a longer poly A tail, and it has a more prolonged half-life compared to XL53.
[0042] Fig. 5 illustrates generation of a chimeric antigen targeted at PDL1 protein, pNBS-XL53-150A. Similar to the discussion in Fig. 1, the transcription of RNA is initiated by the T7 promoter. The 5'-UTR/Kozak region of nucleotides provides significant for initiation of translation. The nucleic acid sequence encoding the CD64 signal peptide is present in the 3' end of the UTR/Kozak region, and it directs nascent protein to ER. This is followed by scFv region, which binds PDL I antigen. A hinge region is present next to the scFv region, and that provides a range of motion to the scFv. The hinge region is followed by a transmembrane domain that allows insertion of the nucleotide construct into the membrane.
This is followed by one or more intracellular domains comprising co-stimulatory and/or signaling elements. Finally, the 3'-UTR and Poly-A regions are present to provide stability to the RNA as well as initiation of translation. The longer poly-A region in this construct provides for an RNA construct with more stability and longer half-life time.
This is followed by one or more intracellular domains comprising co-stimulatory and/or signaling elements. Finally, the 3'-UTR and Poly-A regions are present to provide stability to the RNA as well as initiation of translation. The longer poly-A region in this construct provides for an RNA construct with more stability and longer half-life time.
[0043] Fig. 6 illustrates time course of XL53-150A PDL1 CAR expression post electroporation, while the cytotoxic activity of NK cells transfected with XL53-150A are shown in Fig. 7. The vector map of the XL53-150A construct is shown in Fig. 8.
Finally, Table 2 below shows the different sequence portions of the XL53-150A
construct.
Table 2 pNBS-XL-53(Rbsc6-Construct name CD28CD3z-anti-PDL1) Size 7584 bp 3'UTR Mus Musculus 1-94 hemoglobin alpha Date Recue/Date Received 2021-03-31 polyA 95-116 SV40 polyA signal 433-567 Puromycin resistance gene 572-1171 (reverse) OriP 3187-3753 Ampicillin resistance gene 3842-4702 rrnG tel niinator 4700-4835 EFla promoter 4879-6060 T7 promoter 6068-6086 5'UTR 6087-6192 Kozak sequence 6123-6130 CD64 signal peptide 6132-6176 Rbsc6-VL (variable light 6177-6500 chain) Linker 6501-6560 Rbsc6-VH (variable heavy 6561-6914 chain) CD28 hinge region 6915-7031 CD28 transmembrane domain 7032-7112 CD28 cytoplasmic domain 7113-7235 CD3zeta cytoplasmic domain 7236-7577
Finally, Table 2 below shows the different sequence portions of the XL53-150A
construct.
Table 2 pNBS-XL-53(Rbsc6-Construct name CD28CD3z-anti-PDL1) Size 7584 bp 3'UTR Mus Musculus 1-94 hemoglobin alpha Date Recue/Date Received 2021-03-31 polyA 95-116 SV40 polyA signal 433-567 Puromycin resistance gene 572-1171 (reverse) OriP 3187-3753 Ampicillin resistance gene 3842-4702 rrnG tel niinator 4700-4835 EFla promoter 4879-6060 T7 promoter 6068-6086 5'UTR 6087-6192 Kozak sequence 6123-6130 CD64 signal peptide 6132-6176 Rbsc6-VL (variable light 6177-6500 chain) Linker 6501-6560 Rbsc6-VH (variable heavy 6561-6914 chain) CD28 hinge region 6915-7031 CD28 transmembrane domain 7032-7112 CD28 cytoplasmic domain 7113-7235 CD3zeta cytoplasmic domain 7236-7577
[0044] In another embodiment, the inventors have disclosed the molecule NKW29, which comprises the recombinant nucleic acid construct of SEQ ID NO: 3. This molecule is very similar to the XL53-150A construct except for the following modification: The intracellular domain of the XL53-150A is replaced with the intracellular domain of FccRly.
The main features of this construct are (i) It uses a combination of intracellular domains of CD28 and FcERIy for enhanced cytotoxic activity against target cells; and (ii) it is relatively stable due to the long poly A tail.
The main features of this construct are (i) It uses a combination of intracellular domains of CD28 and FcERIy for enhanced cytotoxic activity against target cells; and (ii) it is relatively stable due to the long poly A tail.
[0045] Fig. 9 illustrates generation of a chimeric antigen targeted at PDL1 protein, NKW29-150A. Similar to the discussion in Figs. 1 and 5, the transcription of RNA is initiated by the T7 promoter. The 5'-UTR/Kozak region of nucleotides provides significant for initiation of translation. The nucleic acid sequence encoding the CD64 signal peptide is present in the 3' end of the UTR/Kozak region, and it directs nascent protein to ER. This is followed by scFv region, which binds PDL1 antigen. A hinge region is present next to the scFv region, and that provides a range of motion to the scFv. The hinge region is followed by a transmembrane domain that allows insertion of the nucleotide construct into the membrane.
This is followed by one or more intracellular domains comprising co-stimulatory and/or signaling elements. The intracellular domain illustrated in Fig. 9 and SEQ ID
NO: 3 is intracellular domain of Fc RIy. Finally, the 3'-UTR and Poly-A regions are present to Date Recue/Date Received 2021-03-31 provide stability to the RNA as well as initiation of translation. The longer poly-A region in this construct provides for an RNA construct with more stability and longer half-life time.
This is followed by one or more intracellular domains comprising co-stimulatory and/or signaling elements. The intracellular domain illustrated in Fig. 9 and SEQ ID
NO: 3 is intracellular domain of Fc RIy. Finally, the 3'-UTR and Poly-A regions are present to Date Recue/Date Received 2021-03-31 provide stability to the RNA as well as initiation of translation. The longer poly-A region in this construct provides for an RNA construct with more stability and longer half-life time.
[0046] Fig. 10 illustrates time course of NKW29-150A PDL1 CAR expression in NK
cells, 24 and 48 hours post electroporation. In vitro transcription was done using Sapl digested NKW29-150A DNA. NK cells were transfected with the in-vitro transcribed RNA
(2ug/1e6 cells). PDL1 expression was determined using flow cytometry and biotinylated PDLl/streptavidin APC.
cells, 24 and 48 hours post electroporation. In vitro transcription was done using Sapl digested NKW29-150A DNA. NK cells were transfected with the in-vitro transcribed RNA
(2ug/1e6 cells). PDL1 expression was determined using flow cytometry and biotinylated PDLl/streptavidin APC.
[0047] The vector map of the NKW29-150A construct is shown in Fig. 11.
Finally, Table 3 below shows the different sequence portions of the NKW29-150A construct.
Table 3 Construct name Size 7493 bp SV40 polyA signal 271-405 Puromycin resistance gene 1009-410 Ampicillin resistance gene 58-918 imG terminator 916-1051 EFla promoter 2-1183 T7 promoter 1191-1209 5'UTR 1210-1252 Kozak sequence 1246-1253 CD64 signal peptide 1254-1299 Rbsc6-VL (variable light 1300-1623 chain) Linker 1624-1683 Rbsc6-VH (variable heavy 1684-2037 chain) CD28 hinge region 2038-2154 CD28 transmembrane domain 2155-2235 CD28 cytoplasmic domain 2236-2358 Fce RIy cytoplasmic domain 2359-2484 3' UTR Mus Muscu/us 2492-2585 hemoglobin alpha polyA 2592-2741
Finally, Table 3 below shows the different sequence portions of the NKW29-150A construct.
Table 3 Construct name Size 7493 bp SV40 polyA signal 271-405 Puromycin resistance gene 1009-410 Ampicillin resistance gene 58-918 imG terminator 916-1051 EFla promoter 2-1183 T7 promoter 1191-1209 5'UTR 1210-1252 Kozak sequence 1246-1253 CD64 signal peptide 1254-1299 Rbsc6-VL (variable light 1300-1623 chain) Linker 1624-1683 Rbsc6-VH (variable heavy 1684-2037 chain) CD28 hinge region 2038-2154 CD28 transmembrane domain 2155-2235 CD28 cytoplasmic domain 2236-2358 Fce RIy cytoplasmic domain 2359-2484 3' UTR Mus Muscu/us 2492-2585 hemoglobin alpha polyA 2592-2741
[0048] In another embodiment, the inventors have disclosed the XL53-Tri-cistronic molecule, which comprises the recombinant nucleic acid construct of SEQ ID NO:
4. This molecule is similar to XL53 except for it co-expresses 3 genes: PDL1 CAR, CD16a and ER-Date Recue/Date Received 2021-03-31 retained 112. A P2A sequence and an EMCV IRES precede the CD16a and ER-IL2 genes respectively, allow independent translation of these genes. The main features of this construct are: (a) It expresses CD16a that engages in ADCC (antibody dependent cellular toxicity) and further triggers NK cell lysis of the target cells; and (b) It expresses IL-2, a cytokine that is a crucial growth factor for growth and cytotoxic activity of NK cells.
4. This molecule is similar to XL53 except for it co-expresses 3 genes: PDL1 CAR, CD16a and ER-Date Recue/Date Received 2021-03-31 retained 112. A P2A sequence and an EMCV IRES precede the CD16a and ER-IL2 genes respectively, allow independent translation of these genes. The main features of this construct are: (a) It expresses CD16a that engages in ADCC (antibody dependent cellular toxicity) and further triggers NK cell lysis of the target cells; and (b) It expresses IL-2, a cytokine that is a crucial growth factor for growth and cytotoxic activity of NK cells.
[0049] Fig. 12 illustrates generation of a chimeric antigen targeted at PDL1 protein, tricistronic XL53. Similar to the discussion in Fig. 1, the transcription of RNA is initiated by the T7 promoter. The 5'-UTR/Kozak region of nucleotides provides significant for initiation of translation. The nucleic acid sequence encoding the CD64 signal peptide is present in the 3' end of the UTR/Kozak region, and it directs nascent protein to ER. This is followed by scFv region, which binds PDL1 antigen. A hinge region is present next to the scFv region, and that provides a range of motion to the scFv. The hinge region is followed by a transmembrane domain that allows insertion of the nucleotide construct into the membrane.
This is followed by one or more intracellular domains comprising co-stimulatory and/or signaling elements. The co-stimulatory and/or signaling elements are followed by P2A for ribosome entry, CD16a which is significant for ADCC, EMCV which is the ribosome entry site, and ER-IL2. Finally, the 3'-UTR and Poly-A regions are present to provide stability to the RNA as well as initiation of translation. The longer poly-A region in this construct provides for an RNA construct with more stability and longer half-life time.
This is followed by one or more intracellular domains comprising co-stimulatory and/or signaling elements. The co-stimulatory and/or signaling elements are followed by P2A for ribosome entry, CD16a which is significant for ADCC, EMCV which is the ribosome entry site, and ER-IL2. Finally, the 3'-UTR and Poly-A regions are present to provide stability to the RNA as well as initiation of translation. The longer poly-A region in this construct provides for an RNA construct with more stability and longer half-life time.
[0050] Fig. 13 illustrates XL53-tricistronic PDL1 CAR expression 24 hours post electroporation. The cytotoxic activity of CAR-infected cells on MS1 fLuc target cells are shown in Fig. 14. In this case, the transfected cells were mixed with target cells 2 hours post electroporation for overnight incubation. The vector map of the XL53-tricistronic construct is shown in Fig. 15. Finally, Table 4 below shows the different sequence portions of the XL53-tricistronic construct.
Table 4.
XL-53 Tricistronic I. Construct name Size 9496 bp Ampicillin resistance gene 58-918 rrnG terminator 916-1051 EFla promoter 1095-2276 T7 promoter 2284-2302 5'UTR 2303-2345 Date Recue/Date Received 2021-03-31 Kozak sequence 2339-2346 CD64 signal peptide 2348-2392 Rbsc6-VL (variable light 2393-2716 chain) Linker/spacer 2717-2776 Rbsc6-VH (variable heavy 2777-3130 chain) CD28 hinge region 3131-3247 CD28 transmembrane domain 3248-3328 CD28 cytoplasmic domain 3329-3451 CD3zeta cytoplasmic tail 3452-3790 FcyRIIIa (CD16a) 3857-4621 3'UTR Mus Muscu/us 5713-5806 hemoglobin alpha polyA 5807-5828 SV40 polyA signal 6145-6279 Puromycin resistant gene 6284-6883 OriP 8899-9465
Table 4.
XL-53 Tricistronic I. Construct name Size 9496 bp Ampicillin resistance gene 58-918 rrnG terminator 916-1051 EFla promoter 1095-2276 T7 promoter 2284-2302 5'UTR 2303-2345 Date Recue/Date Received 2021-03-31 Kozak sequence 2339-2346 CD64 signal peptide 2348-2392 Rbsc6-VL (variable light 2393-2716 chain) Linker/spacer 2717-2776 Rbsc6-VH (variable heavy 2777-3130 chain) CD28 hinge region 3131-3247 CD28 transmembrane domain 3248-3328 CD28 cytoplasmic domain 3329-3451 CD3zeta cytoplasmic tail 3452-3790 FcyRIIIa (CD16a) 3857-4621 3'UTR Mus Muscu/us 5713-5806 hemoglobin alpha polyA 5807-5828 SV40 polyA signal 6145-6279 Puromycin resistant gene 6284-6883 OriP 8899-9465
[0051] Most currently available CAR technology uses viral vectors as a way of delivery of a DNA molecule to the cells. The viral DNA enters the nucleus and can integrate into the host genome. The inventors have developed a new approach that uses an RNA molecule because RNA only enters the cytoplasm and is ready to be translated. The inventors have overcome the degradation of RNA molecule problem by introducing several elements such as 5' and 3' UTR as well as a long poly-A to improve stability of the molecules disclosed herein.
[0052] Some variations to the inventive concept as contemplated by the inventors would be introduction of different 5' or 3' UTR elements that can improve stability of the RNA
molecule. The construct can also be altered by addition (or swapping) of more co-stimulatory domains. Addition of other cytokine genes to the same construct (as a bi- or tri-cistronic) can also improve activity of the molecule.
molecule. The construct can also be altered by addition (or swapping) of more co-stimulatory domains. Addition of other cytokine genes to the same construct (as a bi- or tri-cistronic) can also improve activity of the molecule.
[0053] In one embodiment, disclosed herein is a recombinant nucleic acid, comprising: a T7 promoter sequence portion, a 5' untranslated (5'-UTR) sequence portion, a signal peptide sequence portion, a single chain antibody fragment sequence portion, a hinge region sequence portion, a transmembrane domain sequence portion, and one or more intracellular domain sequence portions. . The signal peptide sequence portion further comprises a sequence encoding CD64. The RNA formed from the recombinant DNA nucleic acid is stabilized by a Date Recue/Date Received 2021-03-31 5'-UTR sequence portion and/or a Kozak sequence. The Kozak sequence (or Kozak consensus sequence) is a nucleic acid motif that functions as the translation initiation site in most mRNA transcripts. It is regarded as the optimum sequence for initiating translation in eukaryotes, the sequence is an integral aspect of protein regulation. The sequence is generally defined as 5'-(gcc)gccRccAUGG-3' where R indicates a purine (adenine or guanine). Of course, variations of the Kozak sequences are known to skilled artisans and contemplated herein by the inventors.
[0054] The single chain antibody fragment sequence portion of the recombinant nucleic acid comprises a sequence encoding for a single chain variable fragment that is adapted to bind PDL1 antigen. The hinge portion plays the role of providing range of motion for the single chain antibody fragment sequence portion. The transmembrane domain sequence portion enables insertion of the recombinant nucleic acid to a membrane. The intracellular domain sequence portion comprises co-stimulatory or signaling sequence portions such as CD28, CD3c, and/or FccRIy. The intracellular domain sequence portions are selected to provide enhanced cytotoxic activity against tumor cells. The 3'-UTR region towards the 3' end of the recombinant nucleic acid provides stability to the RNA and initiation of translation.
Furthermore, a poly-A sequence portion may be present for additional stability reason. In some embodiments, the poly-A sequence portion comprises at least 150 adenine nucleotides.
In some embodiments, the recombinant nucleic acid may be tri-cistronic ¨ in other words, the nucleic acid may have sequence encoding for PDL1-CAR, CD16a, and ER-IL2.
Furthermore, a poly-A sequence portion may be present for additional stability reason. In some embodiments, the poly-A sequence portion comprises at least 150 adenine nucleotides.
In some embodiments, the recombinant nucleic acid may be tri-cistronic ¨ in other words, the nucleic acid may have sequence encoding for PDL1-CAR, CD16a, and ER-IL2.
[0055] In another aspect of the instant disclosure, provided herein are modified NK cells comprising one or more nucleic acids encoding: a T7 promoter sequence portion, a 5' untranslated (5'-UTR) sequence portion, a signal peptide sequence portion, a single chain antibody fragment sequence portion, a hinge region sequence portion, a transmembrane domain sequence portion, and one or more intracellular domain sequence portions; wherein the nucleic acid sequences are operably linked to each other as a single polynucleotide.
[0056] Natural killer (NK) cells are cells of the immune system that kill target cells in the absence of a specific antigenic stimulus, and without restriction according to major histocompatibility complex (MHC) class. NK cells are characterized by the presence of CD56 and the absence of CD3 surface markers. Endogenous NK cells are generally heterogeneous populations of cells within which NK cells have been enriched.
Endogenous NK cells may be intended for autologous or allogeneic treatment of a patient.
Date Recue/Date Received 2021-03-31
Endogenous NK cells may be intended for autologous or allogeneic treatment of a patient.
Date Recue/Date Received 2021-03-31
[0057] As used herein, "immunotherapy" refers to the use of NK cells modified or unmodified, naturally occurring or modified NK cell or T-cell, whether alone or in combination, and which are capable of inducing cytotoxicity when contacting a target cell.
Treatment of cancer
Treatment of cancer
[0058] Provided herein are methods of treating a cancer or a tumor in a subject, the method comprising administering to the subject a therapeutically effective amount of the modified NK cells as disclosed above or a composition comprising modified NK cells as disclosed above to a patient in need thereof. The administration is contemplated to treat the cancer, reduces the size of the tumor in the subject, or reduce cancer metastasis in the subject.
[0059] The term "cancer" refers to all types of cancer, neoplasm, or malignant tumors found in mammals, including leukemia, carcinomas and sarcomas. Exemplary cancers include cancer of the brain, breast, cervix, colon, head & neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus and Medulloblastoma.
Additional examples include, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine and exocrine pancreas, and prostate cancer.
Additional examples include, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine and exocrine pancreas, and prostate cancer.
[0060] The terms "metastasis," "metastatic," and "metastatic cancer" can be used interchangeably and refer to the spread of a proliferative disease or disorder, e.g., cancer, from one organ or another non-adjacent organ or body part. Cancer occurs at an originating site, e.g., breast, which site is referred to as a primary tumor, e.g., primary breast cancer.
Some cancer cells in the primary tumor or originating site acquire the ability to penetrate and infiltrate surrounding normal tissue in the local area and/or the ability to penetrate the walls of the lymphatic system or vascular system circulating through the system to other sites and tissues in the body. A second clinically detectable tumor formed from cancer cells of a primary tumor is referred to as a metastatic or secondary tumor. When cancer cells metastasize, the metastatic tumor and its cells are presumed to be similar to those of the original tumor. Thus, if lung cancer metastasizes to the breast, the secondary tumor at the site of the breast consists of abnormal lung cells and not abnormal breast cells. The Date Recue/Date Received 2021-03-31 secondary tumor in the breast is referred to a metastatic lung cancer. Thus, the phrase metastatic cancer refers to a disease in which a subject has or had a primary tumor and has one or more secondary tumors. The phrases non-metastatic cancer or subjects with cancer that is not metastatic refers to diseases in which subjects have a primary tumor but not one or more secondary tumors. For example, metastatic lung cancer refers to a disease in a subject with or with a history of a primary lung tumor and with one or more secondary tumors at a second location or multiple locations, e.g., in the breast.
Some cancer cells in the primary tumor or originating site acquire the ability to penetrate and infiltrate surrounding normal tissue in the local area and/or the ability to penetrate the walls of the lymphatic system or vascular system circulating through the system to other sites and tissues in the body. A second clinically detectable tumor formed from cancer cells of a primary tumor is referred to as a metastatic or secondary tumor. When cancer cells metastasize, the metastatic tumor and its cells are presumed to be similar to those of the original tumor. Thus, if lung cancer metastasizes to the breast, the secondary tumor at the site of the breast consists of abnormal lung cells and not abnormal breast cells. The Date Recue/Date Received 2021-03-31 secondary tumor in the breast is referred to a metastatic lung cancer. Thus, the phrase metastatic cancer refers to a disease in which a subject has or had a primary tumor and has one or more secondary tumors. The phrases non-metastatic cancer or subjects with cancer that is not metastatic refers to diseases in which subjects have a primary tumor but not one or more secondary tumors. For example, metastatic lung cancer refers to a disease in a subject with or with a history of a primary lung tumor and with one or more secondary tumors at a second location or multiple locations, e.g., in the breast.
[0061] As used herein, "treating" or "treatment of' a condition, disease or disorder or symptoms associated with a condition, disease or disorder refers to an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of condition, disorder or disease, stabilization of the state of condition, disorder or disease, prevention of development of condition, disorder or disease, prevention of spread of condition, disorder or disease, delay or slowing of condition, disorder or disease progression, delay or slowing of condition, disorder or disease onset, amelioration or palliation of the condition, disorder or disease state, and remission, whether partial or total.
"Treating" can also mean prolonging survival of a subject beyond that expected in the absence of treatment. "Treating" can also mean inhibiting the progression of the condition, disorder or disease, slowing the progression of the condition, disorder or disease temporarily, although in some instances, it involves halting the progression of the condition, disorder or disease permanently. As used herein the terms treatment, treat, or treating refers to a method of reducing the effects of one or more symptoms of a disease or condition characterized by expression of the protease or symptom of the disease or condition characterized by expression of the protease. Thus in the disclosed method, treatment can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of an established disease, condition, or symptom of the disease or condition. For example, a method for treating a disease is considered to be a treatment if there is a 10% reduction in one or more symptoms of the disease in a subject as compared to a control. Thus the reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any percent reduction in between 10% and 100% as compared to native or control levels. It is understood that treatment does not necessarily refer to a cure or complete ablation of the disease, condition, or symptoms of the disease or condition. Further, as used herein, references to decreasing, reducing, or inhibiting include a change of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, Date Recue/Date Received 2021-03-31 90% or greater as compared to a control level and such terms can include but do not necessarily include complete elimination.
"Treating" can also mean prolonging survival of a subject beyond that expected in the absence of treatment. "Treating" can also mean inhibiting the progression of the condition, disorder or disease, slowing the progression of the condition, disorder or disease temporarily, although in some instances, it involves halting the progression of the condition, disorder or disease permanently. As used herein the terms treatment, treat, or treating refers to a method of reducing the effects of one or more symptoms of a disease or condition characterized by expression of the protease or symptom of the disease or condition characterized by expression of the protease. Thus in the disclosed method, treatment can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of an established disease, condition, or symptom of the disease or condition. For example, a method for treating a disease is considered to be a treatment if there is a 10% reduction in one or more symptoms of the disease in a subject as compared to a control. Thus the reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any percent reduction in between 10% and 100% as compared to native or control levels. It is understood that treatment does not necessarily refer to a cure or complete ablation of the disease, condition, or symptoms of the disease or condition. Further, as used herein, references to decreasing, reducing, or inhibiting include a change of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, Date Recue/Date Received 2021-03-31 90% or greater as compared to a control level and such terms can include but do not necessarily include complete elimination.
[0062] The terms subject, patient, individual, etc. are not intended to be limiting and can be generally interchanged. That is, an individual described as a patient does not necessarily have a given disease, but may be merely seeking medical advice. As used throughout, a subject can be a vertebrate, more specifically a mammal (e.g., a human, horse, cat, dog, cow, pig, sheep, goat, mouse, rabbit, rat, and guinea pig), birds, reptiles, amphibians, fish, and any other animal. The term does not denote a particular age or sex. Thus, adult and newborn subjects, whether male or female, are intended to be covered. As used herein, patient, individual and subject may be used interchangeably and these terms are not intended to be limiting. That is, an individual described as a patient does not necessarily have a given disease, but may be merely seeking medical advice. The terms patient or subject include human and veterinary subjects.
[0063] "Administration" or "administering," as used herein, refers to providing, contacting, and/or delivering a compound or compounds by any appropriate route to achieve the desired effect. Administration may include, but is not limited to, oral, sublingual, parenteral (e.g., intravenous, subcutaneous, intracutaneous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional or intracranial injection), transdermal, topical, buccal, rectal, vaginal, nasal, ophthalmic, via inhalation, and implants. Optionally, the NK cells are administered parenterally. Optionally, the NK cells are administered intravenously. Optionally, the NK cells are administered peritumorally.
[0064] The modified NK cells as disclosed herein can be administered to a subject by absolute numbers of cells, e.g., said subject can be administered from about cells/injection to up to about 10 billion cells/injection, such as at about, at least about, or at most about, 1x10' , 1x109, 1x108, 1x107, 5x107, 1x106, 5x106, 1x105, 5x105, 1x104, 5x104, 1x103, 5x103 (and so forth) NK cells per injection, or any ranges between any two of the numbers, end points inclusive. Optionally, from 1x108 to lx101 cells are administered to the subject. Optionally, the cells are administered one or more times weekly for one or more weeks. Optionally, the cells are administered once or twice weekly for 1, 2, 3, 4, 5, 6, 7, 8, 9, or more weeks.
Date Recue/Date Received 2021-03-31
Date Recue/Date Received 2021-03-31
[0065] In another embodiment, the total dose may also calculated by m2 of body surface area.
The subject may be administered from about 1000 cells/injection/m2 to up to about 10 billion cells/injection/m2, such as at about, at least about, or at most about, 1 x10 mina2, 1x109/m2, 1x108/m2, 1x107/m2, 5x107/1112, X106/1112, 5x106/M2, 1X105/1112, 5x105/M2,X104/1112, 5x104/m2, 1x103/m2, 5x103/m2 (and so forth) NK cells per injection, or any ranges between any two of the numbers, end points inclusive. Optionally, from 1x103 to lx101 , per m2 of the NK cells are administered to the subject. Optionally, 2x109 per m2, of the NK cells are administered to the subject.
The subject may be administered from about 1000 cells/injection/m2 to up to about 10 billion cells/injection/m2, such as at about, at least about, or at most about, 1 x10 mina2, 1x109/m2, 1x108/m2, 1x107/m2, 5x107/1112, X106/1112, 5x106/M2, 1X105/1112, 5x105/M2,X104/1112, 5x104/m2, 1x103/m2, 5x103/m2 (and so forth) NK cells per injection, or any ranges between any two of the numbers, end points inclusive. Optionally, from 1x103 to lx101 , per m2 of the NK cells are administered to the subject. Optionally, 2x109 per m2, of the NK cells are administered to the subject.
[0066] Optionally, NK cells can be administered to such individual by relative numbers of cells, e.g., said individual can be administered about 1000 cells to up to about 10 billion cells per kilogram of the individual, such as at about, at least about, or at most about, lx1010, 1x109, 1x108, 1x107, 5x107, 1x106, 5x106, 1x105, 5x105, 1x104, 5x104, 1x103, 5x103 (and so forth) NK cells per kilogram of the individual, or any ranges between any two of the numbers, end points inclusive.
[0067] In some embodiments, NK cells are administered in a composition comprising NK
cells and a medium, such as human serum or an equivalent thereof. The medium may comprise human serum albumin and/or human plasma. Optionally, the medium comprises about 1% to about 15% human serum or human serum equivalent. Optionally, the medium comprises about 1% to about 10% human serum or human serum equivalent.
Optionally, the medium comprises about 1% to about 5% human serum or human serum equivalent.
Optionally, the medium comprises about 2.5% human serum or human serum equivalent.
Optionally, the serum is human AB serum. Optionally, a serum substitute that is acceptable for use in human therapeutics is used instead of human serum. Such serum substitutes may be known in the art. Optionally, NK cells are administered in a composition comprising NK
cells and an isotonic liquid solution that supports cell viability.
Optionally, NK cells are administered in a composition that has been reconstituted from a cryopreserved sample.
cells and a medium, such as human serum or an equivalent thereof. The medium may comprise human serum albumin and/or human plasma. Optionally, the medium comprises about 1% to about 15% human serum or human serum equivalent. Optionally, the medium comprises about 1% to about 10% human serum or human serum equivalent.
Optionally, the medium comprises about 1% to about 5% human serum or human serum equivalent.
Optionally, the medium comprises about 2.5% human serum or human serum equivalent.
Optionally, the serum is human AB serum. Optionally, a serum substitute that is acceptable for use in human therapeutics is used instead of human serum. Such serum substitutes may be known in the art. Optionally, NK cells are administered in a composition comprising NK
cells and an isotonic liquid solution that supports cell viability.
Optionally, NK cells are administered in a composition that has been reconstituted from a cryopreserved sample.
[0068] According to the methods provided herein, the subject is administered an effective amount of one or more of the agents provided herein. The terms effective amount and effective dosage are used interchangeably. The term effective amount is defined as any amount necessary to produce a desired physiologic response (e.g., reduction of inflammation). Effective amounts and schedules for administering the agent may be determined empirically by one skilled in the art. The dosage ranges for administration are Date Recue/Date Received 2021-03-31 those large enough to produce the desired effect in which one or more symptoms of the disease or disorder are affected (e.g., reduced or delayed). The dosage should not be so large as to cause substantial adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like. Generally, the dosage will vary with the age, condition, sex, type of disease, the extent of the disease or disorder, route of administration, or whether other drugs are included in the regimen, and can be determined by one of skill in the art.
The dosage can be adjusted by the individual physician in the event of any contraindications.
Dosages can vary and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. For example, for the given parameter, an effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Efficacy can also be expressed as "-fold" increase or decrease.
For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control. The exact dose and formulation will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Remington:
The Science and Practice of Pharmacy, 22nd Edition, Gennaro, Editor (2012), and Pickar, Dosage Calculations (1999)).
The dosage can be adjusted by the individual physician in the event of any contraindications.
Dosages can vary and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. For example, for the given parameter, an effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Efficacy can also be expressed as "-fold" increase or decrease.
For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control. The exact dose and formulation will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Remington:
The Science and Practice of Pharmacy, 22nd Edition, Gennaro, Editor (2012), and Pickar, Dosage Calculations (1999)).
[0069] The provided methods may be further combined with other tumor therapies such as radiotherapy, surgery, hormone therapy and/or immunotherapy. Thus, the provided methods can further include administering one or more additional therapeutic agents to the subject.
Suitable additional therapeutic agents include, but are not limited to, analgesics, anesthetics, analeptics, corticosteroids, anticholinergic agents, anticholinesterases, anticonvulsants, antineoplastic agents, allosteric inhibitors, anabolic steroids, antirheumatic agents, psychotherapeutic agents, neural blocking agents, anti-inflammatory agents, antihelmintics, antibiotics, anticoagulants, antifungals, antihistamines, antimuscarinic agents, antimycobacterial agents, antiprotozoal agents, antiviral agents, dopaminergics, hematological agents, immunological agents, muscarinics, protease inhibitors, vitamins, growth factors, and hormones. The choice of agent and dosage can be determined readily by one of skill in the art based on the given disease being treated. Optionally, the additional therapeutic agent is octreotide acetate, interferon, pembrolizumab, glucopyranosyl lipid A, carboplatin, etoposide, or any combination thereof.
Date Recue/Date Received 2021-03-31
Suitable additional therapeutic agents include, but are not limited to, analgesics, anesthetics, analeptics, corticosteroids, anticholinergic agents, anticholinesterases, anticonvulsants, antineoplastic agents, allosteric inhibitors, anabolic steroids, antirheumatic agents, psychotherapeutic agents, neural blocking agents, anti-inflammatory agents, antihelmintics, antibiotics, anticoagulants, antifungals, antihistamines, antimuscarinic agents, antimycobacterial agents, antiprotozoal agents, antiviral agents, dopaminergics, hematological agents, immunological agents, muscarinics, protease inhibitors, vitamins, growth factors, and hormones. The choice of agent and dosage can be determined readily by one of skill in the art based on the given disease being treated. Optionally, the additional therapeutic agent is octreotide acetate, interferon, pembrolizumab, glucopyranosyl lipid A, carboplatin, etoposide, or any combination thereof.
Date Recue/Date Received 2021-03-31
[0070] In some embodiments, the additional therapeutic entity may be selected from the group consisting of a viral cancer vaccine, a bacterial cancer vaccine, a yeast cancer vaccine, N-803, an antibody, a stem cell transplant, and a tumor targeted cytokine.
[0071] Optionally, the additional therapeutic agent is a chemotherapeutic agent. A
chemotherapeutic treatment regimen can include administration to a subject of one chemotherapeutic agent or a combination of chemotherapeutic agents.
Chemotherapeutic agents include, but are not limited to, alkylating agents, anthracyclines, taxanes, epothilones, histone deacetylase inhibitors, inhibitors of Topoisomerase I, inhibitors of Topoisomerase II, kinase inhibitors, monoclonal antibodies, nucleotide analogs and precursor analogs, peptide antibiotics, platinum-based compounds, retinoids, and vinca alkaloids and derivatives.
Optionally, the chemotherapeutic agent is carboplatin.
chemotherapeutic treatment regimen can include administration to a subject of one chemotherapeutic agent or a combination of chemotherapeutic agents.
Chemotherapeutic agents include, but are not limited to, alkylating agents, anthracyclines, taxanes, epothilones, histone deacetylase inhibitors, inhibitors of Topoisomerase I, inhibitors of Topoisomerase II, kinase inhibitors, monoclonal antibodies, nucleotide analogs and precursor analogs, peptide antibiotics, platinum-based compounds, retinoids, and vinca alkaloids and derivatives.
Optionally, the chemotherapeutic agent is carboplatin.
[0072] Combinations of agents or compositions can be administered either concomitantly (e.g., as a mixture), separately but simultaneously (e.g., via separate intravenous lines) or sequentially (e.g., one agent is administered first followed by administration of the second agent). Thus, the term combination is used to refer to concomitant, simultaneous, or sequential administration of two or more agents or compositions. The course of treatment is best determined on an individual basis depending on the particular characteristics of the subject and the type of treatment selected. The treatment, such as those disclosed herein, can be administered to the subject on a daily, twice daily, bi-weekly, monthly, or any applicable basis that is therapeutically effective. The treatment can be administered alone or in combination with any other treatment disclosed herein or known in the art. The additional treatment can be administered simultaneously with the first treatment, at a different time, or on an entirely different therapeutic schedule (e.g., the first treatment can be daily, while the additional treatment is weekly).
[0073] In some embodiments, the numbers expressing quantities of ingredients, properties such as concentration, reaction conditions, and so forth, used to describe and claim certain embodiments of the invention are to be understood as being modified in some instances by the term "about." Accordingly, in some embodiments, the numerical parameters set forth in the written description and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by a particular embodiment. The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated Date Recue/Date Received 2021-03-31 herein, each individual value is incorporated into the specification as if it were individually recited herein.
[0074] It should further be noted that the terms "prognosing" or "predicting"
a condition, a susceptibility for development of a disease, or a response to an intended treatment is meant to cover the act of predicting or the prediction (but not treatment or diagnosis of) the condition, susceptibility and/or response, including the rate of progression, improvement, and/or duration of the condition in a subject. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context.
The use of any and all examples, or exemplary language (e.g. "such as") provided with respect to certain embodiments herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
a condition, a susceptibility for development of a disease, or a response to an intended treatment is meant to cover the act of predicting or the prediction (but not treatment or diagnosis of) the condition, susceptibility and/or response, including the rate of progression, improvement, and/or duration of the condition in a subject. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context.
The use of any and all examples, or exemplary language (e.g. "such as") provided with respect to certain embodiments herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
[0075] As used in the description herein and throughout the claims that follow, the meaning of "a," "an," and "the" includes plural reference unless the context clearly dictates otherwise.
Also, as used in the description herein, the meaning of "in" includes "in" and "on" unless the context clearly dictates otherwise. As also used herein, and unless the context dictates otherwise, the term "coupled to" is intended to include both direct coupling (in which two elements that are coupled to each other contact each other) and indirect coupling (in which at least one additional element is located between the two elements). Therefore, the terms "coupled to" and "coupled with" are used synonymously.
Also, as used in the description herein, the meaning of "in" includes "in" and "on" unless the context clearly dictates otherwise. As also used herein, and unless the context dictates otherwise, the term "coupled to" is intended to include both direct coupling (in which two elements that are coupled to each other contact each other) and indirect coupling (in which at least one additional element is located between the two elements). Therefore, the terms "coupled to" and "coupled with" are used synonymously.
[0076] It should be apparent to those skilled in the art that many more modifications besides those already described are possible without departing from the inventive concepts herein.
The inventive subject matter, therefore, is not to be restricted except in the scope of the appended claims. Moreover, in interpreting both the specification and the claims, all terms should be interpreted in the broadest possible manner consistent with the context. In particular, the terms "comprises" and "comprising" should be interpreted as referring to elements, components, or steps in a non-exclusive manner, indicating that the referenced elements, components, or steps may be present, or utilized, or combined with other elements, components, or steps that are not expressly referenced. Where the specification claims refers to at least one of something selected from the group consisting of A, B, C
.... and N, the text Date Recue/Date Received 2021-03-31 should be interpreted as requiring only one element from the group, not A plus N, or B plus N, etc.
Date Recue/Date Received 2021-03-31
The inventive subject matter, therefore, is not to be restricted except in the scope of the appended claims. Moreover, in interpreting both the specification and the claims, all terms should be interpreted in the broadest possible manner consistent with the context. In particular, the terms "comprises" and "comprising" should be interpreted as referring to elements, components, or steps in a non-exclusive manner, indicating that the referenced elements, components, or steps may be present, or utilized, or combined with other elements, components, or steps that are not expressly referenced. Where the specification claims refers to at least one of something selected from the group consisting of A, B, C
.... and N, the text Date Recue/Date Received 2021-03-31 should be interpreted as requiring only one element from the group, not A plus N, or B plus N, etc.
Date Recue/Date Received 2021-03-31
Claims (11)
1. A recombinant nucleic acid, comprising:
a T7 promoter sequence portion, a 5' unuanslated (5'-UTR) sequence portion, a signal peptide sequence portion, a single chain antibody fragment sequence portion, a hinge region sequence portion, a transmembrane domain sequence portion, and one or more intracellular domain sequence portions; and wherein the nucleic acid has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%
or 99% identity to any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4.
a T7 promoter sequence portion, a 5' unuanslated (5'-UTR) sequence portion, a signal peptide sequence portion, a single chain antibody fragment sequence portion, a hinge region sequence portion, a transmembrane domain sequence portion, and one or more intracellular domain sequence portions; and wherein the nucleic acid has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%
or 99% identity to any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4.
2. The recombinant nucleic acid of claim 1, wherein the hinge sequence portion provides range of motion for the single chain antibody fragment sequence portion.
3. The recombinant nucleic acid of claim 1 or 2, wherein the transmembrane domain sequence portion enables insertion of a transmembrane domain encoded by the transmembrane domain sequence portion into a membrane.
4. The recombinant nucleic acid of any one of claims 1-3, wherein the one or more intracellular domain sequence portions comprise CD28 and/or CD3c
5. The recombinant nucleic acid of any one of claims 1-3, wherein the one or more intracellular domain sequence portions comprise CD28 and/or Ratty.
6. The recombinant nucleic acid of any one of claims 1-5, wherein the one or more intracellular domain sequence portions provide enhanced cytotoxic activity against tumor cells.
7. The recombinant nucleic acid of any one of claims 1-6, wherein the recombinant nucleic acid is in a vector.
Date Recue/Date Received 2022-07-28
Date Recue/Date Received 2022-07-28
8. The recombinant nucleic acid of any one of claims 1-7, further comprising a sequence portion encoding CD16a.
9. The recombinant nucleic acid of any one of claims 1-8, further comprising a sequence portion encoding ER-1L2.
10. A method of generating CAR-NK cells, comprising: transfecting a primary NK cell with a recombinant nucleic acid of any one of claims 1-9.
11. A recombinant cell comprising the recombinant nucleic acid of any one of claims 1-9, wherein the cell is a bacterial cell or wherein the cell is an autologous NK
cell, or wherein the NK cell is genetically modified.
Date Recue/Date Received 2022-07-28
cell, or wherein the NK cell is genetically modified.
Date Recue/Date Received 2022-07-28
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2019/063454 WO2021107940A1 (en) | 2019-11-26 | 2019-11-26 | Primary nk car constructs and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
CA3113962A1 CA3113962A1 (en) | 2021-05-26 |
CA3113962C true CA3113962C (en) | 2023-10-24 |
Family
ID=76088912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3113962A Active CA3113962C (en) | 2019-11-26 | 2019-11-26 | Primary nk car constructs and methods |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220282216A1 (en) |
EP (1) | EP4065695A4 (en) |
JP (1) | JP2022539931A (en) |
KR (3) | KR20240096830A (en) |
CN (2) | CN118147081A (en) |
AU (2) | AU2019468311B2 (en) |
CA (1) | CA3113962C (en) |
IL (1) | IL282319A (en) |
SG (1) | SG11202103528VA (en) |
WO (1) | WO2021107940A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023004255A2 (en) * | 2021-07-21 | 2023-01-26 | Immunitybio, Inc. | GENERATION OF CHIMERIC ANTIGEN RECEPTOR mRNA MOLECULES FOR EXPRESSION IN PRIMARY NK CELLS |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2656414T3 (en) * | 2010-09-08 | 2018-02-27 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
US9833476B2 (en) * | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
ES2716298T3 (en) * | 2011-09-16 | 2019-06-11 | Baylor College Medicine | The tumor microenvironment as a target through the use of manipulated NKT cells |
US20150329640A1 (en) * | 2012-12-20 | 2015-11-19 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
EP2970426B1 (en) * | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
CN107073138B (en) * | 2015-03-02 | 2018-06-29 | 上海斯丹赛生物技术有限公司 | Reduce the immunological tolerance induced by PD-L1 |
AU2016274989A1 (en) * | 2015-06-12 | 2017-11-02 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
WO2017167217A1 (en) * | 2016-04-01 | 2017-10-05 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
CN109419818B (en) * | 2017-08-24 | 2021-08-10 | 厦门大学 | Echovirus for treating tumors |
WO2019082721A1 (en) * | 2017-10-23 | 2019-05-02 | 日本たばこ産業株式会社 | Construct for expressing g-protein-coupled receptor or sub-unit thereof, and use of said construct |
-
2019
- 2019-11-26 KR KR1020247019177A patent/KR20240096830A/en not_active Application Discontinuation
- 2019-11-26 AU AU2019468311A patent/AU2019468311B2/en active Active
- 2019-11-26 EP EP19946247.4A patent/EP4065695A4/en active Pending
- 2019-11-26 KR KR1020247008007A patent/KR102674654B1/en active IP Right Grant
- 2019-11-26 CA CA3113962A patent/CA3113962C/en active Active
- 2019-11-26 CN CN202410366455.9A patent/CN118147081A/en active Pending
- 2019-11-26 SG SG11202103528VA patent/SG11202103528VA/en unknown
- 2019-11-26 WO PCT/US2019/063454 patent/WO2021107940A1/en active Application Filing
- 2019-11-26 CN CN201980067946.0A patent/CN113302307B/en active Active
- 2019-11-26 JP JP2021520551A patent/JP2022539931A/en active Pending
- 2019-11-26 US US17/311,226 patent/US20220282216A1/en active Pending
- 2019-11-26 KR KR1020217011005A patent/KR102647888B1/en active IP Right Grant
-
2021
- 2021-04-13 IL IL282319A patent/IL282319A/en unknown
-
2023
- 2023-06-30 AU AU2023204206A patent/AU2023204206A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN118147081A (en) | 2024-06-07 |
KR20240096830A (en) | 2024-06-26 |
KR102674654B1 (en) | 2024-06-12 |
CN113302307A (en) | 2021-08-24 |
JP2022539931A (en) | 2022-09-14 |
CN113302307B (en) | 2024-04-05 |
CA3113962A1 (en) | 2021-05-26 |
KR20210068461A (en) | 2021-06-09 |
AU2019468311B2 (en) | 2023-05-18 |
WO2021107940A1 (en) | 2021-06-03 |
US20220282216A1 (en) | 2022-09-08 |
IL282319A (en) | 2021-09-30 |
SG11202103528VA (en) | 2021-07-29 |
EP4065695A4 (en) | 2023-08-09 |
KR102647888B1 (en) | 2024-03-13 |
KR20240037358A (en) | 2024-03-21 |
AU2019468311A1 (en) | 2021-06-10 |
AU2023204206A1 (en) | 2023-08-10 |
EP4065695A1 (en) | 2022-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hou et al. | Navigating CAR-T cells through the solid-tumour microenvironment | |
AU2019314455B2 (en) | A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies | |
US20150017137A1 (en) | Drug resistant immunotherapy for treatment of a cancer | |
US11788093B2 (en) | Chimeric antigen receptor t-cells expressing interleukin-8 receptor | |
EP3344760B1 (en) | Genetically-engineered drug resistant t cells and methods of using the same | |
WO2018098352A2 (en) | Targeting kras induced immune checkpoint expression | |
WO2019084284A1 (en) | Nk cells for use in treating cancer in canines | |
CA3113962C (en) | Primary nk car constructs and methods | |
US20220370558A1 (en) | Combination cancer immunotherapy | |
US20170002351A1 (en) | Compositions and methods for reducing c/ebp homologous protein activity in myeloid-derived suppressor cells | |
JP7407452B2 (en) | Medicines for the treatment and/or prevention of cancer | |
WO2015097210A1 (en) | Immunosuppressive foxa1-expressing t cells | |
US20240139241A1 (en) | Compositions and methods for conditioning patients for cell therapy | |
WO2024000637A1 (en) | Combined pharmaceutical composition for treating tumor and use thereof | |
WO2023212566A1 (en) | Compositions and methods for preventing t cell exhaustion | |
Burger et al. | P07. 01 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28. z cells in recurrent glioblastoma | |
Seifert et al. | P08. 05 Combined pharmacological targeting of adenosine 2a-and 2b-receptor enhances CAR T cell function | |
JP2024526860A (en) | Generation of chimeric antigen receptor mRNA molecules for expression in primary NK cells | |
NZ750663A (en) | Compositions and methods for cancer immunotherapy | |
NZ750663B2 (en) | Compositions and methods for cancer immunotherapy | |
Okamoto et al. | 777. Highly Efficient and Safe Vectors for TCR Gene Therapy: Silencing of Endogenous TCR Improved Expression and Anti-Tumor Reactivity of Transduced Tumor-Specific TCRs in Human Lymphocytes |